Article

Quetiapine augmentation in treatment-resistant depression: a naturalistic study.

Department of Psychiatry, Clinical Hospital Centre Zagreb, Kispatićeva 12, Zagreb, Croatia.
Psychopharmacology (Impact Factor: 3.99). 10/2006; 187(4):511-4. DOI: 10.1007/s00213-006-0452-x
Source: PubMed

ABSTRACT Treatment-resistant depression (TRD) is a common clinical problem, often complicated with suicidal ideations and greater lifetime functional impairment, and represents a considerable challenge to management and treatment.
The aim of a prospective, open-label, noncomparative, flexible-dosed 20-week study was to evaluate the effects of quetiapine, as an add-on therapy, in patients with TRD who were refractory to previous treatments.
Eighteen patients with major depressive disorder (DSM-IV criteria) were treated for 20 weeks with quetiapine (mean dose 315+/-109 mg/day). Patients were evaluated at baseline, weekly from 1 to 9 weeks, and then after 12, 16, and 20 weeks of treatment, using Hamilton rating scale for depression-17 items (HAMD) scale.
Fourteen patients with TRD completed the 20-week open trial with quetiapine. The augmentation with quetiapine significantly reduced total scores and scores listed in the anxiety subscale on the HAMD, and these effects were observed after the fourth week of treatment, while the depressed mood scores were significantly reduced after the fifth week of treatment. Quetiapine add-on treatment significantly decreased the scores listed in the insomnia subscale on the HAMD subscale after the second week of treatment.
Our preliminary data indicate that quetiapine add-on therapy appears to have beneficial effects in the treatment of patients with TRD.

0 Bookmarks
 · 
312 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The safety and efficacy of quetiapine for the treatment of insomnia in adults are reviewed. Quetiapine was developed for the treatment of psychiatric disorders, but its antagonism of histamine H1- and serotonin type 2A receptors has the added effect of causing sedation. As such, quetiapine is widely used off-label as a treatment for insomnia. Due to quetiapine's potential adverse effects, guidelines for the treatment of insomnia have recommended the drug's use only in patients with specific comorbid psychiatric disorders. The use of quetiapine for the treatment of insomnia in the absence of comorbid conditions has been evaluated in only two clinical trials of 31 patients in total, and very few studies have evaluated quetiapine use in patients with insomnia and other comorbidities. No trials have been conducted comparing quetiapine with an active control (e.g., zolpidem); the data that exist compare quetiapine to a placebo or there is no comparison and all patients are treated with quetiapine. Very few studies have evaluated quetiapine's efficacy in the treatment of insomnia using sleep objective testing, another limitation of the available data on quetiapine. Robust studies evaluating the safety and efficacy of quetiapine for the treatment of insomnia are lacking. Given its limited efficacy data, its adverse-effect profile, and the availability of agents approved by the Food and Drug Administration for the treatment of insomnia, quetiapine's benefit in the treatment of insomnia has not been proven to outweigh potential risks, even in patients with a comorbid labeled indication for quetiapine.
    American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists 03/2014; 71(5):394-402. DOI:10.2146/ajhp130221 · 2.10 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The hypothalamic-pituitary-adrenocortical (HPA) system is believed to play an important role in the pathophysiology of major depressive disorder. In this context, the atypical antipsychotic quetiapine (QUE) has been shown to inhibit HPA system activity in healthy subjects. In this study we investigated whether the putative inhibitory effects of QUE on HPA system activity may contribute to its antidepressant efficacy. We analyzed the effects of QUE as an augmentation to the selective serotonin reuptake inhibitor (SSRI) escitalopram (ESC) on HPA system activity in comparison to a monotherapy with ESC in relation to the antidepressant effectiveness. HPA axis activity (cortisol and ACTH) was measured by means of the dexamethasone/corticotropin-releasing hormone (DEX/CRH) test which was performed before (week 0) and during (week 1, week 5) antidepressant psychopharmacotherapy. The combination therapy, but not the ESC monotherapy showed significantly inhibiting effects on HPA system activity leading to stepwise down-regulation. ACTH concentrations were reduced in the ESC/QUE group during five weeks of treatment. The inhibitory effect of QUE may be involved in its antidepressant effects as an augmentation strategy.
    Journal of Psychiatric Research 05/2014; 52. DOI:10.1016/j.jpsychires.2014.01.013 · 4.09 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Today though we have a large number of antidepressants, there are also a large number of patients who do not respond to traditional antidepressant therapy. Various augmentation strategies have been suggested in these cases the foremost being atypical antipsychotic therapy. In fact atypical antipsychotic drugs (aripiprazole and quetiapine) have received US FDA approval as augmenting agents in the treatment of major depression. The present review looks at the various studies of atypical antipsychotics in the management of depression along with efficacy amongst individual drugs. The various mechanisms that may result in antidepressant action by atypical antipsychotics have been discussed along with novel mechanisms that may play a role. The review concludes that atypical antipsychotics have a place in the pharmacotherapy of depression and are useful agents as both augmentation strategies and in the management of treatment resistant depression.

Full-text (3 Sources)

Download
75 Downloads
Available from
Jul 3, 2014